In primary lung cancer, a retrospective study found KRAS-mutant tumors had a significantly higher PD-L1 expression, high CD8+T cells infiltration and higher TMB than EGFR-mutant tumors (Liu et al., 2020). This evidence concerns the gene KRAS and lung cancer.